Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Packaging & closure defects

Failed child-resistant closures, leaks, cracked containers, or a defective delivery device. Packaging failures risk accidental exposure (especially to children) or product contamination.

318 FDA drug recalls with this cause, newest first.

These recalls involve the container rather than the contents - failed child-resistant closures, leaking bags or vials, cracked cartridges, blister packs with holes, or a delivery device (pump, applicator, syringe) that does not work as designed. A seal problem can let contamination in after the product leaves the factory, and a failed child-resistant cap puts children at risk of accidental exposure.

Class II · Moderate risk

Cefdinir for Oral Suspension

Defective Container: This recall is being carried out due to the potential for improperly sealed bottles.

Terminated Packaging defect Teva Pharmaceuticals USA, Inc. NDC 0093-4136-64 D-247-2013
Class II · Moderate risk

Daytrana (methylphenidate)

Defective Delivery System: Out of Specification (OOS) results for the z-statistic value, which relates to the patients and caregiver ability to remove the release liner from the patch adhesive prior to administration, were obtained.

Terminated Packaging defect Noven Pharmaceuticals, Inc. NDC 68968-5552-3 D-312-2013
Class III · Low risk

EstroGel (estradiol gel)

Defective Container: Pump head detaching from the canister unit upon removal of the overcap.

Terminated Packaging defect Ascend Therapeutics Inc D-146-2013
Class II · Moderate risk

Nutropin AQ NuSpin 10

Miscalibrated and/or Defective Delivery System: Genentech has received complaints for Nutropin AQ NuSpin 10 & 20 reporting that the dose knob spun slowly and the injection took longer than usual (slow dose delivery).

Terminated Packaging defect Genentech Inc NDC 50242-0074-01 D-088-2013
Class II · Moderate risk

Nutropin AQ NuSpin 20

Miscalibrated and/or Defective Delivery System: Genentech has received complaints for Nutropin AQ NuSpin 10 & 20 reporting that the dose knob spun slowly and the injection took longer than usual (slow dose delivery).

Terminated Packaging defect Genentech Inc NDC 50242-0076-01 D-087-2013
Class II · Moderate risk

Synthroid (levothyroxine sodium)

Defective Container: A number of Synthroid bottles have a localized thin wall defect on the bottom which may potentially impact the stability of the tablets.

Terminated Packaging defect Abbott Laboratories D-1696-2012
Class II · Moderate risk

Synthroid (levothyroxine sodium)

Defective Container: A number of Synthroid bottles have a localized thin wall defect on the bottom which may potentially impact the stability of the tablets.

Terminated Packaging defect Abbott Laboratories D-1695-2012
Class II · Moderate risk

Synthroid (levothyroxine sodium)

Defective Container: A number of Synthroid bottles have a localized thin wall defect on the bottom which may potentially impact the stability of the tablets.

Terminated Packaging defect Abbott Laboratories D-1694-2012
Class II · Moderate risk

Daytrana (methylphenidate)

Miscalibrated and/or Defective Delivery System: Out of Specification results for mechanical peel force and/or the z-statistic value which relates to the patient's ability to remove the release liner from the patch adhesive prior to administration.

Terminated Packaging defect Noven Pharmaceuticals, Inc. NDC 68968-5553-3 D-1655-2012
Class II · Moderate risk

Daytrana (methylphenidate)

Miscalibrated and/or Defective Delivery System: Out of Specification results for mechanical peel force and/or the z-statistic value which relates to the patient's ability to remove the release liner from the patch adhesive prior to administration.

Terminated Packaging defect Noven Pharmaceuticals, Inc. NDC 68968-5555-3 D-1654-2012
Class II · Moderate risk

Daytrana (methylphenidate)

Miscalibrated and/or Defective Delivery System: Out of Specification results for mechanical peel force and/or the z-statistic value which relates to the patient's ability to remove the release liner from the patch adhesive prior to administration.

Terminated Packaging defect Noven Pharmaceuticals, Inc. NDC 68968-5554-3 D-1653-2012
Class II · Moderate risk

Daytrana (Methylphenidate)

Miscalibrated/Defective Delivery System; exceeded the specification for both mechanical peel force (MPF) and/or the z-statistic value

Terminated Packaging defect Noven Pharmaceuticals, Inc. NDC 68968-5554-01 D-1413-2012
Class II · Moderate risk

Daytrana (methylphenidate)

Miscalibrated and/or Defective Delivery System: Out of Specification results for mechanical peel force and/or the z-statistic value which relates to the patient's ability to remove the release liner from the patch adhesive prior to administration.

Terminated Packaging defect Noven Pharmaceuticals, Inc. NDC 54092-552-01 D-1375-2012
Class II · Moderate risk

Daytrana (methylphenidate)

Miscalibrated and/or Defective Delivery System: Out of Specification results for mechanical peel force and/or the z-statistic value which relates to the patient's ability to remove the release liner from the patch adhesive prior to administration.

Terminated Packaging defect Noven Pharmaceuticals, Inc. NDC 54092-553-01 D-1374-2012
Class II · Moderate risk

Daytrana (methylphenidate)

Miscalibrated and/or Defective Delivery System: Out of Specification results for mechanical peel force and/or the z-statistic value which relates to the patient's ability to remove the release liner from the patch adhesive prior to administration.

Terminated Packaging defect Noven Pharmaceuticals, Inc. NDC 54092-555-01 D-1373-2012
Class II · Moderate risk

Daytrana (methylphenidate)

Miscalibrated and/or Defective Delivery System: Out of Specification results for mechanical peel force and/or the z-statistic value which relates to the patient's ability to remove the release liner from the patch adhesive prior to administration.

Terminated Packaging defect Noven Pharmaceuticals, Inc. NDC 54092-554-30 D-1372-2012